National study reveals disparities in biologic therapy access for non-infectious uveitis, indicating significant impact of payer policy.
Access to biologic therapy for non-infectious uveitis varies by insurance, income, race, sex, and age. Insurance coverage exerted the greatest effect, indicating that payer policy is the main determinant of overall treatment allocation in the U.S. healthcare system.
No takes yet. Share an insight, caveat, or question.
Kamyab et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: